Immunology | Drug Discovery | B cell biology | Autoimmunity
New York, USA
Joined August 2009
- Tweets411
- Following1.1K
- Followers597
- Likes4.2K
Pinned Tweet
Excited to share our new work in @SciImmunology! We describe targeting of gut-associated lymphoid tissue (GALT) as a novel mode of action of anti-α4β7 therapy in IBD. Co-led by @mat_uzz & A. Seki @MehandruLab @SinaiImmunol @MountSinaiGI @IcahnMountSinai🧵
science.org/doi/10.1126/scii…
Pablo Canales-Herrerias retweeted
New study from @RoserTP, @HabibBashour, Filipska, et al. (@victorgreiff & Cerutti labs @UniOslo & @HMar_research) show IgD responses involve a heterogenous population of IgD class-switched memory #Bcells from epithelial areas of the aerodigestive mucosa. hubs.la/Q04dyH9l0
Pablo Canales-Herrerias retweeted
📢 Looking for a #MasterThesis (TFM) opportunity?
Join our lab at University of Barcelona! 🧬Project: Host–microbiota interaction in Crohn’s disease : from systems immunology to antibody engineering.
🔗Contact us to learn more! #translationalImmunology #Microbiome #antibodies
Pablo Canales-Herrerias retweeted
My lab @MBIsg and @NUSMedicine is recruiting a fully-funded postdoc to start in Jan 2026! Interested in cell and tissue mechanics, transcriptional regulation of tissue health, or AI/ML for disease mechanobiology? Come join us in Singapore!
mechano-medicine-lab.com/pos…
Pablo Canales-Herrerias retweeted
Excited to be starting my research group as a tenure track Presidential Young Professor at the Mechanobiology Institute @MBIsg, and the Dept of Physiology at @NUSingapore in the fall! More about our work on vascular mechanobiology: mechano-medicine-lab.com/
Pablo Canales-Herrerias retweeted
Interested in pursuing a PhD thesis in our group in Demark? Interested in droplets, immune cells and cellular functions? Then definitely apply!
phd.health.au.dk/application…
Pablo Canales-Herrerias retweeted
Please RT 🙏!📢My lab at @UniBarcelona is seeking a highly motivated postdoc to lead an exciting new public-private collaborative project (UB, CRG, CSIC, OrikineBio) aimed at testing a potentially game-changing therapy for IBD. If interested, please contact me at gmagri@ub.edu.
Pablo Canales-Herrerias retweeted
Intestinal germinal center B cell reduction in HIV-1 infection is linked to reduced IgA+ plasma cells and systemic inflammation @SciImmunology @francescacossa1 @saurabhmehandru
science.org/doi/10.1126/scii…
Check this out from @francescacossa1 and @MehandruLab 🔥🔥 @SinaiImmunol @MountSinaiGI @SciImmunology 👇
New research from @MehandruLab describes the depletion of germinal center B cells and IgA+ plasma cells in the #GI tracts of people living with #HIV. @francescacossa1
Read more in Science #Immunology: bit.ly/3Yd0Uwg
Pablo Canales-Herrerias retweeted
🎉 Applications are open for the 2025 Pasteur-Paris University PhD Program (PPU)!
Join a global community of researchers and contribute to groundbreaking biomedical discoveries.
📅 Deadline: October 27, 2024
🔗 Apply now: pasteur.fr/en/education/ppu
#research #institutpasteur
Pablo Canales-Herrerias retweeted
According to a Mount Sinai study, Vedolizumab, a mainstay drug for managing ulcerative colitis, appears to work by targeting gut-associated lymphoid tissue.
Read more: mshs.co/3zacgc0
@DOMSinaiNYC @MountSinaiGI #IBD
Pablo Canales-Herrerias retweeted
We are looking for post-docs. Interested in early life human immunity and bioinformatics? We have a number of really interesting projects. Spread the word and please apply! @YalePediatrics @YaleIBIO
Front-line drug for ulcerative colitis found to have additional mechanism of action that until now remained elusive medicalxpress.com/news/2024-… via @medical_xpress
Pablo Canales-Herrerias retweeted
Front-line drug for ulcerative colitis found to have additional mechanism of action that until now remained elusive (Vdz) medicalxpress.com/news/2024-… via @medical_xpress
Pablo Canales-Herrerias retweeted
Out now 🚨 in @AGA_Gastro is your latest update on selective IL-23p19 inhibition in IBD! Amongst other topics featuring discussion of pathogenesis, PD/PK, efficacy, safety, positioning, and more! Together with @JeanFredericCo1 @MehandruLab & @ryanungaro gastrojournal.org/article/S0…
Pablo Canales-Herrerias retweeted
Gut-associated lymphoid tissue may shape drugs' efficacy.
.@pabloimmune & colleagues describe targeting of gut-associated lymphoid tissue as a novel mode of action of anti-α4β7 therapy in IBD via @SciImmunology:
science.org/doi/10.1126/scii…
Thank you for the highlight @ScienceMagazine!
🔦 science.org/doi/10.1126/scie…
📄science.org/doi/10.1126/scii…
Pablo Canales-Herrerias retweeted
How does vedolizumab work in ulcerative colitis patients?
Researchers in a new @SciImmunology study say the drug targets gut-associated lymphoid tissue. Learn more: scim.ag/6KJ
Pablo Canales-Herrerias retweeted
How does vedolizumab work in ulcerative colitis patients?
Researchers in a new @SciImmunology study say the drug targets gut-associated lymphoid tissue. Learn more: scim.ag/6Im
Pablo Canales-Herrerias retweeted
Explore Dr. Saurabh Mehandru's latest research uncovering vedolizumab's impact on gut-associated lymphoid tissue (#GALT) in #IBD treatment. Gain fresh insights into therapeutic response mechanisms:
bit.ly/3QiGUoJ
